leisure time -WSS

leisure time

author：focus 2025-09-30 07:26:05 Page View：8161

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why health records don't always know when patients are dead
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

focus

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

1:03JackSmith,thentheDepartmentofJustice'schiefofthePublicIntegritySection,posesforphotoattheDepartm

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

How I helped Pfizer think through the ethics of Viagra

AdobeTwenty-fiveyearsago,75-year-oldBobDole—formerRepublicanpresidentialcandidateandU.S.senatorfromK

leisure time

explore

focus

How I helped Pfizer think through the ethics of Viagra